Objective: To evaluate microwave thermotherapy as a treatment option for benign prostate hyperplasia (BPH) in patients with chronic retention and an indwelling catheter. Patients and Methods: 24 unselected patients, 53–91 years old (mean age 73 years) with chronic urinary retention and an indwelling catheter were treated with ProstaLund Feedback Treatment®. Patients had had an indwelling catheter for 1–12 months prior to treatment. ProstaLund Feedback Treatment is an enhanced microwave treatment where the actual intraprostatic temperature is monitored and used to control the microwave power. Results: 19 (80%) of the 24 patients were successfully relieved of their indwelling catheter with satisfactory peak flow, residual urine and symptom score. Treatment failed in 5 (20%) out of the 24 cases. The reasons of failure were identified in all 5 cases and indicate that the method may be less suitable in case of a median lobe or large protruding lobes into the bladder. There were no serious complications such as bleeding requiring hospital intervention, sepsis or urine incontinence. Isolated cases of urinary infection occurred. Conclusion: The satisfying outcome of a 1–hour–long out–patient procedure for this patient category suggests that ProstaLund Feedback Treatment may be a good alternative to surgery for BPH patients with chronic retention and an indwelling catheter.

Keywords:
Benign prostatic hyperplasia, Chronic retention, Indwelling catheter, Microwave thermotherapy, Transurethral microwave thermotherapy
1.
De la Rosette J, D’Acona F, Debruyne F: Current status of thermotherapy of the prostate. J Urol 1997;157:430–438.
2.
Wagrell L, Schelin S, Bolmsjö M, Brudin L: High–energy transurethral microwave thermotherapy (TUMT) with intraprostatic temperature monitoring. J Urol 1998;159:1583– 1587.
3.
D’Ancona F, Francisca E, Witjes W, Welling L, Debruyne F, de la Rosette J: High energy thermotherapy (TUMT) versus transurethral resection (TURP) in the treatment of benign prostatic hyperplasia (BPH): Results of a prospective randomized study with a 1–year follow–up. J Urol 1997;158:120–125.
4.
Lu–Yao G, Barry MJ, Chang CH, Wasson JH, Wenneberg JE: Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Urology 1994;44:692–698.
5.
Borboroglu P, Kane C, Ward JF, Roberts JL, Sands JP: Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999;162:1307–1310.
6.
Fowler F, Wennberg J, Timothy R, Barry M, Mulley A, Hanley D: Symptom status and quality of life following prostatectomy. JAMA 1988;259:3018–3022.
7.
Wennberg JE, Barry MJ, Fowler FJ, Mulley A: Outcomes research, PORTs and health care reforms. Ann NY Acad Sci 1993;703:52–62.
8.
D’Ancona F, Francisca E, Witjes W, Welling L, Debruyne F, de la Rosette J: Transurethral resection of the prostate versus high energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: Long–term results. Br J Urol 1998;81:257–264.
9.
Höfner K, Gonnermann O, Oekle M, Kuczyk M, Jonas U: Transurethral microwave thermotherapy and laser treatment. Curr Opin Urol 1997;7:169–179.
10.
Floratos DL, Sonke GS, Francisca EAE, Kiemeney LALM, Kortmann BBM, Debruyne FMJ, de la Rosette JJMCH: High energy transurethral microwave thermotherapy for the treatment of patients in urinary retention. J Urol 2000;163:1457–1460.
11.
Djavan B, Seitz C, Ghawidel K, Basharkhah A, Bursa B, Hruby S, Marberger M: High–energy transurethral microwave thermotherapy in patients with acute urinary retention due to benign prostatic hyperplasia. Urology 1999;54: 18–22.
12.
Pennes HH: Analysis of tissue and arterial blood temperatures in the resting human forearm. J Appl Physiol 1948;1:93–122.
13.
Henriques FC: Studies of thermal injury. Arch Pathol 1947;43:489–502.
14.
Sturesson C, Andersson–Engels S: A mathematical model for predicting the temperature distribution in laser–induced hyperthermia: Experimental evaluation and applications. Phys Med Biol 1995;40:2037–2052.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.